Stocks
Vanda Pharmaceuticals Financial Statements (VNDA) |
||||||||||
| Vanda Pharmaceuticalssmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 03.05.2023 | 28.07.2023 | 09.11.2023 | 08.02.2024 | 09.05.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 62.5 | 46.1 | 38.8 | 45.3 | 47.5 | 177.6 | |||
| Operating Income, bln rub | 2.00 | -2.87 | -6.00 | -7.09 | -9.24 | -25.2 | ||||
| EBITDA, bln rub | ? | 2.67 | -2.49 | -5.62 | -5.94 | -7.01 | -21.1 | |||
| Net profit, bln rub | ? | 3.25 | 1.52 | 0.137 | -2.40 | -4.15 | -4.89 | |||
| OCF, bln rub | ? | 31.8 | -13.2 | -2.05 | -3.73 | 7.57 | -11.4 | |||
| CAPEX, bln rub | ? | 0.051 | 0.055 | 0.024 | 0.253 | 0.007 | 0.339 | |||
| FCF, bln rub | ? | 31.8 | -13.3 | -2.07 | -3.99 | 7.56 | -11.8 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 55.7 | 45.4 | 41.7 | 48.9 | 51.2 | 187.3 | ||||
| Cost of production, bln rub | 4.77 | 3.50 | 3.06 | 3.46 | 5.46 | 15.5 | ||||
| R&D, bln rub | 19.2 | 16.6 | 16.6 | 24.3 | 21.2 | 78.7 | ||||
| Interest expenses, bln rub | 3.52 | 0.000 | 0.000 | 3.52 | 0.000 | 3.52 | ||||
| Assets, bln rub | 644.5 | 641.7 | 641.6 | 648.4 | 652.7 | 652.7 | ||||
| Net Assets, bln rub | ? | 535.7 | 539.9 | 543.1 | 544.9 | 544.0 | 544.0 | |||
| Debt, bln rub | 10.7 | 7.94 | 7.47 | 9.40 | 8.92 | 8.92 | ||||
| Cash, bln rub | 501.5 | 489.4 | 489.9 | 388.3 | 394.1 | 394.1 | ||||
| Net debt, bln rub | -490.8 | -481.4 | -482.4 | -378.9 | -385.2 | -385.2 | ||||
| Ordinary share price, rub | 6.79 | 6.59 | 4.32 | 4.22 | 4.11 | 4.47 | ||||
| Number of ordinary shares, mln | 57.0 | 57.5 | 57.5 | 57.5 | 57.8 | 57.8 | ||||
| Market cap, bln rub | 387 | 379 | 248 | 243 | 237 | 258 | ||||
| EV, bln rub | ? | -104 | -103 | -234 | -136 | -148 | -127 | |||
| Book value, bln rub | 518 | 522 | 526 | 424 | 425 | 425 | ||||
| EPS, rub | ? | 0.06 | 0.03 | 0.00 | -0.04 | -0.07 | -0.08 | |||
| FCF/share, rub | 0.56 | -0.23 | -0.04 | -0.07 | 0.13 | -0.20 | ||||
| BV/share, rub | 9.08 | 9.09 | 9.14 | 7.36 | 7.35 | 7.35 | ||||
| EBITDA margin, % | ? | 4.28% | -5.40% | -14.5% | -13.1% | -14.8% | -11.9% | |||
| Net margin, % | ? | 5.20% | 3.30% | 0.35% | -5.30% | -8.74% | -2.75% | |||
| FCF yield, % | ? | 15.3% | 10.6% | 10.3% | 5.11% | -4.96% | -4.56% | |||
| ROE, % | ? | 2.98% | 2.76% | 2.17% | 0.46% | -0.90% | -0.90% | |||
| ROA, % | ? | 2.48% | 2.32% | 1.83% | 0.39% | -0.75% | -0.75% | |||
| P/E | ? | 24.3 | 25.4 | 21.1 | 96.8 | -48.6 | -52.8 | |||
| P/FCF | 6.55 | 9.39 | 9.72 | 19.6 | -20.2 | -21.9 | ||||
| P/S | ? | 1.51 | 1.59 | 1.17 | 1.26 | 1.34 | 1.45 | |||
| P/BV | ? | 0.75 | 0.73 | 0.47 | 0.57 | 0.56 | 0.61 | |||
| EV/EBITDA | ? | -5.72 | -8.95 | -148.2 | 12.0 | 7.02 | 6.03 | |||
| Debt/EBITDA | -27.1 | -41.9 | -305.7 | 33.3 | 18.3 | 18.3 | ||||
| R&D/CAPEX, % | 37 720% | 30 267% | 69 167% | 9 620% | 302 200% | 23 227% | ||||
| CAPEX/Revenue, % | 0.08% | 0.12% | 0.06% | 0.56% | 0.01% | 0.19% | ||||
| Vanda Pharmaceuticals shareholders | ||||||||||
